Bicycle Therapeutics (NASDAQ:BCYC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC) from a strong sell rating to a sell rating in a research note published on Saturday.

A number of other research firms have also weighed in on BCYC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Jefferies Financial Group restated a “buy” rating and set a $12.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, April 30th. Needham & Company LLC cut their price target on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $13.86.

Bicycle Therapeutics Stock Up 2.6%

NASDAQ BCYC opened at $4.00 on Friday. The company has a market cap of $279.97 million, a PE ratio of -1.47 and a beta of 1.55. Bicycle Therapeutics has a 52 week low of $3.74 and a 52 week high of $9.16. The firm’s 50-day simple moving average is $4.10 and its two-hundred day simple moving average is $4.70.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%.The business had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $4.22 million. As a group, equities research analysts anticipate that Bicycle Therapeutics will post -2.23 EPS for the current year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the transaction, the chief executive officer directly owned 605,408 shares of the company’s stock, valued at $2,585,092.16. This trade represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 9,977 shares of company stock valued at $42,702. Corporate insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BCYC. Clearstead Advisors LLC raised its position in shares of Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after buying an additional 3,262 shares in the last quarter. GAMMA Investing LLC grew its position in Bicycle Therapeutics by 512.9% during the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock worth $33,000 after buying an additional 6,447 shares in the last quarter. Portland Investment Counsel Inc. purchased a new position in Bicycle Therapeutics during the second quarter worth about $64,000. Royal Bank of Canada increased its stake in Bicycle Therapeutics by 35.5% in the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock worth $67,000 after acquiring an additional 3,788 shares during the last quarter. Finally, Brooklyn Investment Group bought a new position in Bicycle Therapeutics in the 4th quarter worth about $69,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.